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Ion channel mutations are an important cause of rare
Mendelian disorders affecting brain, heart, and other
tissues. We performed parallel exome sequencing of
237 channel genes in a well-characterized human
sample, comparing variant profiles of unaffected
individuals to those with the most common neuronal
excitability disorder, sporadic idiopathic epilepsy.
Rare missense variation in knownMendelian disease
genes is prevalent in both groups at similar
complexity, revealing that even deleterious ion
channel mutations confer uncertain risk to an indi-
vidual depending on the other variants with which
they are combined. Our findings indicate that variant
discovery via large scale sequencing efforts is only
a first step in illuminating the complex allelic archi-
tecture underlying personal disease risk. We
propose that in silico modeling of channel variation
in realistic cell and network models will be crucial
to future strategies assessingmutation profile patho-
genicity and drug response in individuals with
a broad spectrum of excitability disorders.
INTRODUCTION
Voltage- and ligand-gated ion channels comprise one of the
largest and best-understood functional groups of proteins, with
over 400 members spanning nearly 1% of the human genome.
Channels are ubiquitously expressed in human tissues, and
extensive evolutionary, anatomical, biophysical, and pharmaco-
logical information on key pore-forming and regulatory subunits
in each family is available (Jegla et al., 2009; Nusser, 2009;
Vacher et al., 2008; Wulff et al., 2009). Ion channels are multi-
meric protein complexes expressed in cell type-specific combi-
nations and exert unique yet functionally overlapping control
over excitability and signaling in both the plasma membrane1036 Cell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc.and intracellular organelles. Despite this essential role, nearly
half of channel genes are unstudied, and their broader involve-
ment in non-current-related transmembrane and nuclear
signaling pathways remains largely unexplored (Kaczmarek,
2006; Matzke et al., 2010). Mendelian mutations link single
channel defects with an expanding array of familial episodic
and degenerative excitability disorders in the nervous (Catterall
et al., 2008), cardiovascular (Demolombe et al., 2005), neuroen-
docrine (Hiriart and Aguilar-Bryan, 2008; Roepke et al., 2009;
Ryan et al., 2010), and immune surveillance systems (Cahalan
and Chandy, 2009). Sporadic channel variants are also emerging
as prime candidates for risk in complex psychiatric (Huffaker
et al., 2009), metabolic (Holmkvist et al., 2009), and metastatic
disease (Sontheimer, 2008) and alter ligand binding to the
targets of hundreds of clinically valuable drugs (Drolet et al.,
2005; Liu et al., 2003; Wulff et al., 2009). Their central position
in the biology and therapy of excitability disorders, combined
with the imminent arrival of gene-directed medicine, provides
compelling reasons to explore genomic variation in this
exemplary gene set in order to correctly diagnose, predict, and
treat a broad spectrum of common human disease (Tucker
et al., 2009).
Emerging reports of allelic variability within known disease
genes in healthy individuals raise concern that ‘‘genetic noise’’
may confound personal disease prediction, which will fail in the
absence of a ‘‘healthy’’ reference genome (Lupski et al., 2010;
Ng et al., 2010). Population-based studies can provide a statis-
tical measure of genetic risk as well as implicate novel disease
loci, but individualized disease prediction requires identifying
how genetic variants contribute to risk in a single individual
(Durbin et al., 2010; Manolio et al., 2009). For many common
disorders, beginning with cancer (Knudson et al., 1975), it has
long been hypothesized that the appearance and severity of
the disorder are a simple result of the net accumulation of
genetic variants or ‘‘hits’’ in a disease pathway, where crossing
an undefined risk threshold divides affected from unaffected
individuals (Fraser, 1976; Wray and Goddard, 2010). While
recent data suggest that this assumption may hold true in
some neurological disorders (Davis et al., 2011), it is less clear
Table 1. Summary of Validated Single-Nucleotide Polymorphisms in 237 Ion Channel Genes Profiled in Cases of Idiopathic
Generalized Epilepsy and Neurologically Normal Individuals
Number of Validated SNPs per Megabases Sequencedf
Type/Location
of SNP
Number of
Validated SNPsa
Percent of Validated
Data Set (%)
Number of Novel
SNPs Discovered
Cases Only
(n = 152)
Controls Only
(n = 139)
SNPs in Both Cases
and Controls (n = 291)
Promoterb 80 2.6 18 0.4 0.1 0.4
50 UTR 79 2.6 7 0.2 0.1 0.5
30 UTR 461 14.9 62 1.4 0.6 3.0
Synonymous (sSNP) 936 30.2 351 5.1 2.2 4.2
Nonsynonymous (nsSNP) 668 21.6 415 4.9 2.2 1.9
Nonsense/stop codon 9 <1 9 0.1 0.03 0
Splice site SNPc 12 <1 9 0.1 0.03 0.02
Splice region SNPd 90 2.9 13 0.3 0.1 0.6
Intron SNP 737 23.8 101 2.3 1.0 4.7
Undefinede 23 <1 4 0.1 0 0.2
Totals 3095 100.0 989 14.6 6.3 15.6
See also Figure S1 and Tables S1, S2, S3, and S4.
a Validated SNPs are SNPs are those that were confirmed through a combination of (1) visual validation, (2) previous discovery (dbSNP ID), (3) detected
on a custom MIP chip, and (4) Biotage and/or 454 sequencing.
b SNPs in promoter regions are reported as such if the promoter for the gene is known and defined in our gene models.
c Splice site (+2 to –2 bp from the defined exon boundary at/near the splice junction).
d Splice region (–2 to –15 bp from the defined exon boundary, located in the intron, from the splice junction).
e Undefined SNPs are SNP detected in regions that are not defined in our gene models.
f The number of individual SNPs per megabase sequenced does not reflect the SNP frequency.in the case of ion channels, which display extensive overlapping
compensatory control of membrane excitability, as well as
dynamic homeostatic regulation during brain development and
disease (Marder and Tang, 2010).
Here, we performed comparisons of exomic single-nucleotide
polymorphism (SNP) profiles, including the type, relative burden,
and pattern of variants within a large ion channel candidate gene
set between healthy unaffected individuals and those with
severe neurological excitability disease to evaluate personal
genetic liability, and explored the value of computational models
to assist in personal risk prediction. Epilepsy with no known
cause (idiopathic epilepsy [IE]) is an ideal condition to study
the impact of sporadic genetic channel variation on cortical
function, as seizure disorders affect 1%–2% of the population,
and analyses of the rare Mendelian forms reveal that ion chan-
nels are major determinants of the phenotype, since 17/20
confirmed monogenic syndromes arise in individuals heterozy-
gous for a SNP in a channel subunit gene (Reid et al., 2009).
We observed remarkable genetic complexity and overlapping
patterns of both rare and common variants in known excitability
disease genes across both populations, indicating that the
potential for clinical expression of these common disorders is
embedded in the fabric of all human genomes. A single-cell
computational model of even the simplest pairwise interaction
of two channel mutations reveals the unpredictability of their
collective electrical signature. Given the extent of individual vari-
ation within this large gene family, scaling of multigenic combi-
natorial functional assays to accurately reflect neural network
behavior is impractical. Therefore, personalized ion channel
disease prediction will require the integration of genomic profiles
with single-cell proteomics and computational modeling ofdynamic circuit behavior to translate unique channel variant
portfolios into more informative predictors of personal risk for
excitability disorders.
RESULTS
Profiles of Human Ion Channel Gene Variation Reveal
Striking Individuality
We performed targeted Sanger sequencing of the coding
regions of 237 ion channel subunit genes to expand novel SNP
discovery within known pathogenic channels, their nearest
phylogenetic relatives, and others previously unexplored by
medical resequencing. We examined exonic variation in 139
healthy, neurologically unaffected adults and 152 individuals of
similar age and race with IE. The ion channel gene list (Table
S1 available online) and comprehensive validated SNP data
(Table S2) are provided in the Supplemental Information.
We analyzed more than 9 million base pair reads, yielding
11,102 SNPs (Table S3). From these we assembled a validated
dataset of 3095 SNPs that included all SNP types in similar
proportions to those observed in the unvalidated set (Table 1
and Table S3). Not all known members of the 400+ gene family
nor their still ill-defined promoter regions could be included for
sequencing, and only the first 50 bp of flanking intronic regions
were examined. Insertions and deletions (Indels) and copy
number variants (CNVs) were not reliably detected. While we
considered only exonic SNPs for subsequent evaluation, much
variation occurred in the noncoding regions (introns, untrans-
lated regions [UTRs], and promoters), which can nevertheless
lead to altered gene transcription (McDaniell et al., 2010).
Thus, despite extensive sequence information, our dataCell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc. 1037
significantly underestimates the potential density of variants per
gene, as well as the extent of variation in each individual’s ion
channel sequence variation profile (‘‘channotype’’).
First, we evaluated the variation in channel genes, including
known alternatively spliced isoforms, in our validated data set.
We discovered 989 novel SNPs, of which 351 are synonymous
SNPs (sSNPs), 415 are nonsynonymous SNPs (nsSNPs), and
nine are nonsense mutations (Table 1). Of these novel SNPs,
387 were ‘‘rare,’’ defined as present in a solitary individual
when more than 145 individuals were genotyped at that position
(<1%minor allele frequency [MAF]). The largest genes (Figure S1
and Table S4), RYR1, RYR2, and RYR3, were among those with
themost variation (95, 88, and 57 SNPs, respectively). The small-
est,HTR1B, had six SNPs, including three novel nsSNPs. Collec-
tively, these data expand the known channel SNP lists in dbSNP
and confirm the existence of rare allelic variation across a broad
spectrum of ion channel genes. The rich variation agrees with
that emerging from whole-genome sequencing of individuals
(Durbin et al., 2010; Wheeler et al., 2008), and from more than
2100 cases screened for variants in a subset of clinically impor-
tant cardiac channel genes (Kapplinger et al., 2009). An individ-
ual’s channotype is apparently unique; in our small cohort, we
found that no individuals were free of SNPs, and no two channo-
types among 291 individuals were identical (Figure 1). Across
both groups, we found an overlapping variety of SNP types,
including sSNPs, nsSNPs, and SNPs in promoter, coding,
UTR, and intronic regions. Nonsense SNPs were observed in
both populations. We found SNPs in both groups for every
targeted gene; of the validated SNPs, 1355 were unique to either
population and the majority (1740) were shared (Table 1).
Rare Severe Ion Channel SNPs Do Not Predict Sporadic
Disease
Truncated channel proteins resulting from nonsense mutations
can cause epilepsy (Claes et al., 2001). Similarly, splice site
mutations are implicated in channel disease due to dropout of
exons from the coding messenger RNA (mRNA) (Tsuji et al.,
2007). Although variants of these most functionally ‘‘severe’’
types rarely occur in our data set, the four nonsense and eight
splice site variants with an observed MAF < 0.05 appeared to
be enriched in the IE group (Table 1). We randomly shuffled all
genotype class labels, one SNP at a time, and then tallied the
variants by group again, this time under the null hypothesis. After
10,000 such permutations, a comparison of the observed tally
against the null distribution resulted in a false discovery rate
(FDR) of 0.11. These results indicate that the numerical enrich-
ment observed when comparing rare severe SNPs between
cases and controls occurs more than 11%of the time by random
chance alone. To test whether other SNP types were involved,
we expanded the number of SNPs considered functionally
severe by biochemical classification. We examined all missense
SNPs for their relative rarity and then used a Blosum80 substitu-
tion matrix to score the amino acid substitution caused by the
nsSNP as a predictor of its potential to alter ion channel behavior
(Table S2 and Figure S2). Analysis of missense SNPs with MAF <
0.05 yielded 205 nsSNPs in the predicted deleterious range
(6 to 0). When these SNPs were included in the permutation
analysis with the nonsense and splice site SNPs, the results1038 Cell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc.again did not reach significance (FDR = 0.59). Increasing the
stringency to evaluate only very rare severe SNPs (MAF < 0.01;
n = 171) yielded a FDR of 0.50. Finally, we considered only
very rare nsSNPs with a Blosum80 score of 6 (MAF < 0.01;
n = 38) because these represent the most biochemically disrup-
tive substitutions (e.g., Arg/Cys). After 2000 permutations, the
FDR was 0.25. This increased stringency for the most destabiliz-
ing amino acid mutations still failed to reach significance. Collec-
tively, this unbiased analysis of SNP severity in the coding
regions of 237 ion channel genes from our small study population
provides no evidence for an ion channel rare variant association
in idiopathic epilepsy.
Mendelian Disease Gene SNP Variants Appear
in Both Cases and Controls
We next compared variation within the 17 known ion channel
genes causing familial human epilepsy (hEP genes) (Table S1).
We found that 96.1% of cases and 66.9% of controls had
amissensemutation in at least one known hEP gene. The finding
of missense variants in disease-producing ion channels in unaf-
fected individuals is not new. A smaller scale study of one ion
channel (SCN5A) involved in the cardiac arrhythmia LQT3
syndrome revealed that 3% of 295 unaffected Caucasians
have rare missense mutations in this gene (Ackerman et al.,
2004). However, we found 300 missense channel variants in
139 unaffected individuals, 23 of which are in hEP genes,
signaling that the variable penetrance of alleles in channelopathy
is underappreciated (Figure 2). The R393H nsSNP in the ion
selective pore of the SCN1A gene, believed to cause severe
myoclonic epilepsy of infancy (Claes et al., 2001), was also de-
tected once in our study, and only in the control population. Inter-
estingly, in vitro functional studies of this mutation failed to
produce measurable sodium current (Ohmori et al., 2006), indi-
cating that deleterious alterations in protein structure in a known
hEP gene are insufficient to predict risk of epilepsy. The
unexpectedly common finding of missense mutations in known
hEP genes in our control cohort supports a biophysical model
that other subunits, as yet unrelated to epilepsy, may constitute
genetic excitability modifiers and provides direct evidence
validating the multigenic basis for complex inheritance of chan-
nelopathy phenotypes.
Examining the Load Hypothesis in the hEP Ion Channel
Pathway
An attractive mechanism relating monogenic familial epilepsy to
multigenic sporadic IE is the load hypothesis, which suggests
that if IE is the result of accumulating mutations of small effect
in known disease genes, then the ‘‘load’’ or summation of those
deleterious mutations will surpass some liability threshold
contributing to the overt excitability phenotype. We analyzed
hEP gene profiles in both groups and observed that 77.6% of
cases and, surprisingly, 29.5% of controls have missense muta-
tions in two or more hEP genes. Superficially, the simple numer-
ical excess of mutations in known hEP genes appears to favor
the disease phenotype. However, the most extreme control
showed seven missense mutations in hEP genes, while the
most extreme case had nine, indicating that the specific type
and pattern of mutation rather than number is an overriding
Figure 1. Multiple Variants Render Each Individual Channotype Unique
(A) Low-resolution (gray background) 3D representations illustrating themost extreme channotypes present in the study cohort (two cases and two controls, each
with > 450 SNPs). The columns list the channel subunit genes in alphabetical order (ANK–SCN) and the rows list validated individual SNP identifiers organized
alphabetically by type (30 UTR–promoter). An enlargement at left in teal is presented for clarity and scale. The gene dosage of the minor (variant) allele for a SNP is
denoted by a bar (tall red, homozygous minor allele; short blue, heterozygous minor allele). Sparsely populated regions present in all four channotypes reflect
low-frequency novel SNPs.
(B) Histogram of all individuals by cohort with the total number of SNPs in the individual plotted against the total number of SNPs in the channotype that are
heterozygous or homozygous. The affected and control cohorts show similar allelic dosages with increasing SNP count.
(C) Histogram of all individuals within each cohort showing the total number of SNPs per individual plotted against number of nsSNPs contained in the
channotype. The number of nsSNPs in a channotype increases with increasing total SNP count in both populations.
The individual channotypes profiled in panel (A) (A1, A2, C1, and C2) are indicated in the histograms.
See also Figure S1.
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Figure 2. Known Monogenic Human Epilepsy Genes Populated with Missense and Nonsense Variants Found in Our Study Cohort
The protein products of twelve ion channel genes known to cause monogenic epilepsy are shown schematically. Validated missense and nonsense SNPs
discovered by profiling are represented by circles marking the nearest amino acid location as determined by comparative multiple alignment. Presence of a SNP
denoted by the fill pattern (filled circle, in affected only; open circle, in controls only; half-filled circle, SNP is present in both groups). The nsSNPs in dbSNP are
colored black, novel nsSNPs from our study are colored red, and the nonsense SNPs are colored blue.consideration (Figure 3). Individuals in both groups often carry
multiple, potentially functionally interacting (both intra- and inter-
genic) variants, some of which are shared between populations.
In addition, unique profiles of nsSNPs in hEP genes are defined
by pattern despite the same numerical load (Figure 3). A simple
hEP load hypothesis is therefore confounded by two factors:
(1) gene dosage, which correlates imperfectly with allelic
penetrance at the protein level, and (2) the presence of multiple
missense SNPs in the same gene that may perturb protein
structure in a nonadditive way (Figure 3). Inclusion of all other
missense mutations in the hEP SNP load analysis added
complexity without increasing the power to predict phenotype.
For example, among the highest hEP variant-bearing individuals,
the most extreme case bore 97 nsSNPs in a total of 62 genes,
compared to the most extreme control with 86 nsSNPs in
59 genes.1040 Cell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc.Personal Patterns of Complexity Emerge from Variants
in Intragenic and Epistatic Modifiers
While specific channel subunits have been identified as Mende-
lian hEP genes, variants in other members of their gene families
may potentiate or suppress similar membrane currents and alter
or mask pathological phenotypes. Since voltage and ligand-
gated ion channels assemble as heteromeric complexes with
differing stoichiometry, the combinatorial impact of multiple
nsSNPs among subunits is felt across both voltage and ligand-
gated channel types. For example, examination of sodium
channel homologs revealed that 50.7% of cases and 14.4% of
controls had two or more nsSNPs in their sodium channel genes
(Figure 4). Simultaneous coexpression of different sodium
channel alpha subunit variants in transgenic mice has been
shown to bidirectionally modify epilepsy phenotypes (Hawkins
et al., 2011; Singh et al., 2009). Ligand-gated channels provide
a second example of complex subunit interactions occurring in
both cases and controls. Pentameric GABA receptors form chlo-
ride channels that are composed of alpha, beta, and gamma
subunits, and dysfunction in members of each (GABRA1,
GABRB3, and GABRG2) are linked to epilepsy. We found that
24.3% of cases had two or more nsSNPs in one of the six
GABA receptor alpha subunits; this number was also found in
6.5% of controls; 14.5% of cases had two or more nsSNPs in
one of the three beta subunits compared with 5.0% of controls.
In the three gamma subunits, 1.3% of cases had two or more
nsSNPs, while control individuals only contained single
missense mutations (17.1%).
Given the large SNP variation observed in the control popula-
tion, and that the majority of SNPs are shared between both
groups (Table 1), we considered the possibility that disease
causing nsSNPs are masked in the control populations by other
SNPs, and found similar patterns of complexity in control chan-
notypes. These occurred either as a second intragenic hit in the
same subunit, or heterogenically, where the physiological
summation of pathogenic variants in two (ormore) subunits could
effectively cancel the impact of the deleterious SNP, as shown in
mouse models of digenic calcium and potassium channel muta-
tion interactions (Glasscock et al., 2007). We looked for this
particular gene family combination in our human cohorts, and
found it in both controls (12/139) and cases (55/152). Similarly,
we observed combinations of calcium and sodium channel
missense mutations in both groups (cases 23/152; controls 7/
139) (Figure 4). Interestingly, a few individuals in both populations
(two controls; six cases) had rare nsSNP combinations across
three (SCN, KCN, and CACN) gene families.
Single-Cell Computational Modeling of Allelic
Complexity
Although widely distributed throughout brain circuits, it is
instructive to assess the potential impact of individual intragenic
and epistatic interactions beginning within a single cell. We
adapted a classic computational model of a single CA3 hippo-
campal neuron to simulate gain or loss of function alleles in ion
currents in order to demonstrate that pairwise combinations
(different personal profiles) produce dramatic variation in firing
patterns given a constant ‘‘two-hit’’ load (Bower and Beeman,
2007; Traub et al., 1991). If a simple load effect based on equiv-
alent gain/loss of function among two depolarizing currents was
operative, we would expect similar emergent firing patterns
between two-hit models (e.g., Figure 5A3 versus Figure 5A4
and Figure 5B3 versus Figure 5B4). However, the combinatorial
affects on firing behavior are dramatically more complex, indi-
cating that the pattern of genetic variation (functional valence
of each allele) overrides the load even at the single cell level.
The addition of a third hit can also suppress or aggravate spon-
taneous rhythmic bursting, and important cellular determinant of
neural network behavior (Figure 5C).
DISCUSSION
Appreciation of complex channel variation has far-ranging impli-
cations for understanding the individuality of higher nervous
system function, and defines critical areas for future researchto translate genomic profiling into even rudimentary risk predic-
tion in common sporadic disease (Choi et al., 2009; Gargus,
2003). Here, we examined how functional SNP severity and
patterns of channel nsSNP variation differ among individuals
and uncovered three general findings of immediate clinical
significance for personalized prediction: first, that the architec-
ture of ion channel variation in both groups consists of dense
and highly complex patterns of common and rare alleles;
second, that structural variants in both known and suspected
epilepsy genes appear in otherwise healthy individuals; and
third, that individuals with epilepsy typically carry more than
one mutation in known human epilepsy genes.
A Variant Pattern Hypothesis for Ion Channelopathy
Due to this robust and ubiquitous genetic heterogeneity, we
propose that personalized channel SNP pathogenicity in
complex disease must, at a minimum, be defined in the context
of all other channel subunits present, and that causality cannot
be assigned to any particular variant, even those that are known
to be functionally deleterious. Many potentially pathogenic vari-
ants in known dominant channel genes for epilepsy appear in
otherwise healthy individuals in our study, leading us to suggest
a channel variant pattern hypothesis rather than mutational load
as an oligogenic mechanism for both sporadic epilepsy and
protection from disease. Because of their overlapping voltage
dependence, even physically noninteracting channel proteins
can modulate distantly related channel genes within the same
membrane compartment through changes in transmembrane
potential. This oligogenic electrical relationship integrates
channel alleles within the tissue, and likely plays a role even in
‘‘monogenic’’ channelopathies, since carriers of such mutations
often show a spectrum of clinical phenotypes, including the
absence of disease, even within the same pedigree (Scheffer
et al., 2007). Both in vitro functional expression studies (Rusconi
et al., 2007) and transgenic mouse models combining epilepsy
gene mutations (Glasscock et al., 2007; Hawkins et al., 2011;
Martin et al., 2007; Singh et al., 2009; Song et al., 2004) have
demonstrated that the functional impact of an additional muta-
tion can exacerbate or mask the excitability disorder. Thus,
phenotypic variation in epilepsy and other excitability disorders
may arise from a diverse array of channel alleles at a single locus,
or a constellation of novel alleles in related or distant subunit
genes, and here we show both are abundant. Finally, without
excluding many other biological pathways that could further
modify network excitability (Noebels, 2003), the high incidence
of rare variants implicates the ion channel family itself as
a preeminent source of candidate background modifier genes
for the clinical expression of ion channel disorders, a mechanism
that could help explain both the efficacy of, and pharmacoresist-
ance to, antiepileptic drugs that nonspecifically modulate
multiple ionic currents.
In contrast, we found little evidence or biological rationale for
a SNP load effect in ion channelopathy. We found abundant
channel gene variation in both groups, yet no significant enrich-
ment in singleton-SNPs within affected individuals, and
conclude that biologically, absolute numerical counts of SNP
burden hold little predictive value as a global pathogenic
measure. The detection of a nsSNP allows little insight into itsCell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc. 1041
Figure 3. Channotype Complexity Comparisons for Individuals with Three nsSNPs in Known hEP Genes Reveal Unique Patterns
(A) Individual channotype profiles of four cases and four controls each having three missense mutations among four known hEP genes (CACNA1A, SCN1A,
CLCN2, and KCNQ2), but in distinct patterns that cannot be described by a simple numerical count of ‘‘load.’’ Affected 1, Affected 2, Control 1, and Control 2 all
have three missense mutations in three hEP genes. Control 1 and Affected 1 share the same channotype profile with identical mutations in SCN1A, CLCN2, and
KCNQ2. Affected 3 and Control 3 both have three mutations in two hEP genes, and Affected 4 and Control 4 have the same three nsSNPs in the single CLCN2
gene.
(B) The total number of affected or control individuals with nsSNPs in known hEP genes showing the proportion of individuals with one, two, or three nsSNPs in the
same hEP gene.
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functional effect. The magnitude of ion flux among channels,
even within a family, is highly variable; single channel conduc-
tance in different channels ranges from 1–250 picosiemens
(Harmar et al., 2009), and since the SNPs in individual genes
are of unequal functional valence, a simple tally of variants
across genes without regard to the amplitude of their gain or
loss of function, would obscure the net magnitude of their contri-
bution to network excitability. The cell type and brain region
where the channel isoforms reside, along with their expression
levels during development add further complexity. Finally, even
when a mutant transcript is expressed in both excitatory and
inhibitory cells (potentially counterbalancing the net excitability
changes within a microcircuit), the impact of the channelopathy
may still be inexplicably uneven. For example, an important
epilepsy-related sodium channel gene, SCN1A, is expressed in
both hippocampal pyramidal cells and interneurons, yet haploin-
sufficiency reduces sodium currents only in interneurons; this
discrepancy may explain the powerful network hyperexcitability
underlying Dravet Syndrome, a severe epilepsy of infancy
(Yu et al., 2006). Thus, while membrane current profiles are addi-
tive within an electrotonic compartment of a single cell, the sum
of genomic channel SNPs poorly predicts the emergent physi-
ology of local and long-range networks throughout the entire
nervous system.Toward an Integrated Systems Biology Platform
for Clinical Ion Channel Risk Prediction
With the arrival of discovery platforms capable of efficiently
discriminating all ion channel variation in an individual, and in
the absence of high throughput systems for evaluating oligo-
genic combinatorial functional effects in their appropriate cellular
context (Tomaselli, 2010), the ability to extract predictive pheno-
typic information on network behavior from ion channel SNP
profiles presents a formidable bioinformatic challenge. Fortu-
nately, current advances in converging technologies will help
overcome this complexity. Positional information on channel
subunit expression and stoichiometry in identified brain cells is
being generated by medium (laser-capture) (Okaty et al.,
2009), and higher throughput (bac-trap) methods (Dougherty
et al., 2010), and can be combined with neuroproteomic
databases evaluating subcellular channel composition within
critical neuronal compartments, including dendritic spines,
axon initial segment, and pre-synaptic membrane terminals
(Baye´s and Grant, 2009; Baye´s et al., 2011; Bloodgood et al.,
2009; Mu¨ller et al., 2010; Takamori et al., 2006). New computa-
tional approaches, such as quasi-active modular simulations
(Kellems et al., 2009) of specific channel combinations at
specialized sites are in development (Winden et al., 2009). As
algorithms predicting realistic neuronal firing patterns in relevant
brain microcircuits are developed, the integration of genomic
variation in a matrix with cellular localization in human brain
may provide a platform to assess the personalized electrical(C) Population distribution of nsSNP load found in the hEP genes. Both affected
disease genes.
(D) Histogram of all individuals by cohort with the total number of nsSNPs per indiv
control channotypes cannot be reliably distinguished by nsSNP count in hEP gesignature of an oligogenic variant profile on disease-specific
networks (Clancy and Rudy, 1999; Dyhrfjeld-Johnsen et al.,
2007; Goaillard et al., 2009; Grashow et al., 2009; Gurkiewicz
and Korngreen, 2007; Okaty et al., 2009; Thomas et al., 2009;
Tobin et al., 2009; Toledo-Rodriguez et al., 2005; Xu and Clancy,
2008).
While predicting disease severity by incorporating ion channel
genomic profiles will require these new tools, exome screening
to pinpoint variants with specific effects on drug binding offers
a more immediate role for large-scale channel profiling to
contribute to gene-directed medical therapy (Sheets et al.,
2010). In epilepsy, nearly one-third of patients are refractory to
current AED treatments, which with few exceptions, target ion
channels. Sequence variants that alter access to drug binding
sites are obvious candidate mechanisms for pharmacoresist-
ance (Drolet et al., 2005; Liu et al., 2003), and variant profiles
may personalize treatment by identifying ineffective drugs in
epilepsy and other excitability disorders where channel modula-
tion is clinically useful.EXPERIMENTAL PROCEDURES
Study Population Structure
We evaluated all self-reported white Caucasian and white Hispanic individuals
regardless of the age or gender examined at Baylor College of Medicine
(BCM)-affiliated hospitals in accordance with the guidelines of the BCM
Institutional Review Board. Race and ethnicity were established according
to Risch et al. (Tang et al., 2005) based on a structured questionnaire that
examined the racial and ethnic origin of an individual back three generations
on either side of the family tree. Demographic characteristics of the cohort
are detailed in Table S5. DNA from individuals recruited into the study
(both cases and controls) was sent to the Coriell Institute for Medical Research
for archiving in their cell line repository and is accessible upon request
(http://ccr.coriell.org/Sections/Collections/NINDS/Epilepsy/). Please note
that the samples we have provided Coriell are not differentiated from the
other ‘‘epilepsy’’ samples in the repository.Cases
Cases meeting the accepted criteria for either idiopathic or cryptogenic
epilepsy (Commission on Classification and Terminology of the International
League Against Epilepsy, 1989) were recruited in accordance with the
approved study protocol. In the proposed new classification, the terms ‘‘idio-
pathic’’ and ‘‘cryptogenic’’ have been revised in favor of the term ‘‘genetic
epilepsy’’ when describing the underlying etiology of the disorder (Berg
et al., 2010), and includes seizures occurring in epilepsy patients with
presumed genetic origin.Clinical Assessment
Study subjects were evaluated for epilepsy by board-certified neurologists ac-
cording to a standard protocol for the diagnostic evaluation of their epilepsy.
The neurological assessment was classified as abnormal if deficits such as
hemiparesis, ataxia, or cognitive impairment were present. The presence of
clumsiness or other ‘‘soft’’ neurological signs was insufficient to classify
a patient as having neurological abnormalities. A structured questionnaire
was used to collect information from the patient and any witnesses to the
seizures to complement data recorded in the clinic chart.and control individuals have multiple variants within known epilepsy causing
idual plotted against number of nsSNPs in the known hEP genes. Affected and
nes.
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Figure 5. Computational Model of a Single
Hippocampal Neuron Simulates the Effect
of Varying the Allelic Pattern as a Gain or
Loss of Function in a ‘‘Two-Hit’’ and in
a ‘‘Three-Hit’’ Functional Mutation Profile
A simplified Traub (1991) CA3 pyramidal neuron
was used to test the effects of mutational pattern
in a ‘‘two-hit’’ load paradigm.
(A andB) the gain (up arrow) or loss (down arrow) of
function (defined as a 50% change in peak con-
ductance) of essential ionic currentsweremodeled
in combination. A change in Nav conductance is
complimented by a change in corresponding Cav
(A) or Kv (B) conductance. The ‘‘normal’’ (default
conductance) firingbehavior is shown in red traces;
the input stimulus of 0.1 nA and scale bar is the
same for all panels. Each simulation produces
a strikingly different firing pattern.
(C) Excitability change incorporating an additional
mutant channel shows further dependence on the
allelic pattern. When the two-hit model (50%
increase in Cav and Kv conductance) is supple-
mented by a third hit in Nav, where a simulated
variant showing a gain (250% increase) or a loss
(75% reduction) of Nav conductance is added, the
neuron generates spontaneous (untriggered)
burst discharges; however, the second burst is
shifted toward the normal interburst interval when
Nav is increased (above) and greatly prolonged
with reduced action potential firing when Nav is
decreased (below). The input stimulus of 0.2 nA
and scale bar is the same for all panels.Electroencephalographic Evaluations
All study patients underwent at least one of the following: (1) routine sleep-
deprived electroencephalogram (EEG), (2) prolonged ambulatory (A-EEG), orFigure 4. Intragenic and Epistatic Variants of Known hEP Genes Underlie Individual Complexit
(A) A 3D representation illustrating unique missense channotype profiles from 14 individuals of the voltage-g
cases (n = 7) and controls (n = 7) selected from less extreme (85th percentile) profiles for nsSNP load (60–80 n
subunit with the pore forming alpha subunits listed before accessory subunits and the rows represent the sam
The number of missense (nsSNP) mutations present in the gene is denoted by bar height (gray, no nsSNP; sho
blue, three nsSNPs).
(B) The total number of affected or control individuals with nsSNPs in the 26 voltage gated calcium channe
multiple SNPs in the same gene.
(C) Population distribution of nsSNP load in the calcium channel genes by subunit type. Individuals in both
subunit genes, with the highest nsSNP load being observed in a control individual.
Cell 145, 1036–104(3) video EEG (V-EEG) monitoring. EEG studies
were reviewed and interpreted according to Inter-
national League Against Epilepsy (ILAE) standards
by neurologists board-certified in clinical neuro-
physiology at the Baylor Comprehensive Epilepsy
Center.
Imaging Studies
Brain magnetic resonance imaging (MRI) was
performed in all seizure subjects in accordance
with standard protocol. Visual analysis of obli-
que and coronal T1, T2, and FLAIR images
was done at BCM-affiliated hospitals. Epileptic
seizures and syndromes were classified with
information obtained from the history, physical
evaluation, and above-specified ancillary diag-nostic investigations according to ILAE guidelines (Commission on Classi-
fication and Terminology of the International League Against Epilepsy,
1989).y
ated calcium (CACN) and sodium (SCN) genes for
sSNPs in Figure 1C). The columns list the channel
e individual channotype across both gene families.
rt yellow, one nsSNP; medium red, two nsSNPs; tall
l genes showing the proportion of individuals with
populations have multiple variants in one or more
8, June 24, 2011 ª2011 Elsevier Inc. 1045
Controls
Control subjects were recruited among unrelated visitors, spouses, significant
others, and friends of patients. The clinical assessment of controls was limited
to answers to a structured general medical questionnaire with specific
emphasis on any neurological or cardiac symptoms, including recurrent spells
or seizure-like episodes. Only individuals with an entirely negative past and
present history were included. Individuals with a family history positive for
any neurological disorder outside of cerebrovascular disease and undocu-
mented headache were also excluded.
Ion Channel Gene Targets and Gene Models
We selected all known ion channelopathy genes, their family members and
functionally similar ion channels (Harmar et al., 2009). This list includes
members of both the voltage-gated, ligand-gated and background ‘‘leak’’
channels, and a small number of ion channel interacting proteins like ANK2
(ankyrin-B). Ion channel gene models were defined with the annotations avail-
able through the UCSC Genome Browser for the hg17 assembly from March
2004. Exon boundaries were defined using Refseq coordinates where avail-
able. All reported splice isoforms were included for sequencing. Protein
sequences from in silico translation of each transcript model were aligned to
the reported protein sequence in PubMed. Manual curation of a handful of
gene models was required to reconcile discrepancies. Gene models are avail-
able on request.
Amplicon Definition and Primer Design
Amplicons selected for PCR amplification and downstream sequencing were
single exons smaller than 600 bp in size. For exons larger than 500 bp, multiple
amplicons were subdivided to allow for optimal product lengths but still span
the entire exon with overlapping ends. When two or more exons with the span-
ning intron were collectively less than 500 bp in size, the total region was
defined as a single amplicon for primer design. This consolidation reduced
the number of targets by 10%. For ion channel gene targets in which alterna-
tive isoforms exist, all undefined exons (alternatively spliced exons) were tar-
geted as amplicons and reference cDNA sequences from NCBI for the alterna-
tive isoform were used for annotation. Primers were designed as 20-mers and
were placed 50 bp from either end of an amplicon to ensure accurate reads at
the exon/intron boundaries. Primers were generated automatically with
Primer3, and primer sequences are available on request.
Extraction and Archiving of Genomic DNA
After counseling and informed consent, two vials of 8 ml of blood were drawn
from each individual. Genomic DNA was extracted with the Gentra Puregene
Blood Kit (QIAGEN) and stored in deidentified bar coded tubes prior to use in
amplicon generation. Samples of high-quality, high-molecular-weight
genomic DNA were also sent to the Coriell Sample Repository for cell line
archiving and are openly accessible (http://www.coriell.org/, Home/ Collec-
tions/ NINDS/ Epilepsy).
High-Throughput Parallel Sanger Sequencing
A high-throughput, parallel Sanger sequencing pipeline was designed to
move multiple samples through the amplification, sequencing and subse-
quent SNP detection at one time. All PCR reactions were performed in
a 25 ml reaction volume containing 20–40 ng of individual genomic DNA,
10 pmol of each primer and 12.5 ul of QIAGEN muliplex PCR master mix.
General PCR conditions were initial denaturation and activation step 15 min
at 95C, followed by 30 cycles of the following: denaturation 94C for 30 s,
annealing 50C–65C (depending on target) for 90 s, followed by a 1 min
extension step at 72C. A final 10 min completion step at 72C followed
amplification. Sequencing was performed with Big Dye Terminator Cycle
Sequencing v3.1 and visualized with an ABI3700 (PE Applied Biosystems).
Sequencing chromatograms were compared to reference gene models and
single-nucleotide polymorphisms (SNPs) were detected and annotated using
SNPdetector v3.0 (Zhang et al., 2005), and individual channotypes were
output for analysis. Validation of SNPs included in this study was performed
by visual confirmation of the chromatogram data, the presence of the SNP
in dbSNP, the generation of a custom MIP chip, and a combination of Biotage
and/or 454 sequencing.1046 Cell 145, 1036–1048, June 24, 2011 ª2011 Elsevier Inc.Permutation Bioinformatic Analysis
To assess the enrichment and predictive power of rare variants within our
study population, we performed a permutation-based rare variant enrichment
test for case-control studies that accounts for amplicon-specific group over-
sampling. After filtering for the desired SNPs and corresponding genotypes,
we observed the number of minor alleles in each group. Any observed enrich-
ment of rare variants in either group was compared against the null distribution
generated by 10,000 permutations (random shuffling) of the group labels (case
versus control) to determine the false discovery rate.
Multiple Alignments for Schematic Models
For every nucleotide reference sequence (NM_number) used in this study, we
obtained the corresponding protein sequences (NP_number) in NCBI. Protein
alignments for all members of a gene family that were structurally related (e.g.,
SCN1A-SCN11A or GABRG1-GABRG3) were performed using the MUSCLE
webserver (Edgar, 2004a, 2004b). For the human epilepsy (hEP) genes, struc-
tural models with reference comparative alignments or annotated amino acid
sequence were obtained from the literature. These models were used to posi-
tion individual nonsense or missense mutations on schematic representations
of channel structure.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and four tables and can be
found with this article online at doi:10.1016/j.cell.2011.05.025.
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